Aarti Drugs Ltd. Share Price

Aarti Drugs erases 6.5% gain despite Q2 profit jump

Aarti Drugs shares hit an 11-month high on 4 Nov 2026 but closed 2.25% lower after Q2 profit rose 83.2%. Support is at 430 and resistance at 500. Aarti Drugs Limited [AARTIDRUGS] shares gained as much as 6.5% in morning trade on 4 November 2026 and touched an 11-month high. The gains faded before the close, and the stock ended the session 2.25% lower. The move followed Q2 consolidated results. Profit rose 83.2% year on year to Rs 82.9 crore, against Rs 45.3 crore. Revenue grew 26.6% to Rs 826.2 crore from Rs 652.8 crore. Profit grew faster than revenue, which points to stronger earnings growth in the quarter. A reversal from a high, on the day of strong results, shows buyers did not follow through. In my view, the fade from the high makes the setup cautious in the short term. Resistance sits at 500. A move above 500 would bring a continuation of the rally into focus. Support is at 430, and a fall below 430 would put a deeper pullback in view. Watch whether price holds above 430 in the next sessions and how it reacts near 500. Stance: cautious while price trades between 430 and 500. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.

Aarti Drugs rises as Q2 profit climbs 83.2%

Aarti Drugs gained over 6.5% on 4 November 2026 as Q2 profit rose 83.2%. Rs 535 is resistance, while Rs 450 remains the key support level today. Aarti Drugs Ltd. [ AARTIDRUGS ] rose more than 6.5% in morning trade on 4 November 2026. Its consolidated Q2 profit increased 83.2% year on year to Rs 82.9 crore from Rs 45.3 crore. Revenue grew 26.6% year on year to Rs 826.2 crore from Rs 652.8 crore. Profit grew faster than revenue, pointing to stronger earnings growth in the quarter. The share has rallied 34.7% from its 24 October 2026 low. The current price is 475, 12.6% from the Rs 535 resistance. Rs 450 is the stated support. In my view, short-term momentum remains bullish after the sharp advance, though the rally may pause or see profit-taking. A move above Rs 535 would bring further strength into focus. A fall below Rs 450 would weaken the bullish view and put the advance under pressure. Watch the price reaction near Rs 535 and whether Rs 450 holds on a decline. The current price and chart structure should be checked against the latest trading screen. Stance: bullish in the short term while above Rs 450, with Rs 450 as the key support. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.

Aarti Drugs posts 16% PAT growth, new MD takes charge

AARTIDRUGS Aarti Drugs Ltd has recently reported strong financial results with FY26 consolidated PAT rising 16% to ₹195 crore, alongside a leadership transition where Adhish P. Patil has taken over as Managing Director effective October 2026. The stock has shown bullish technical momentum, trading around ₹379–402 with recent gains of over 6%. 📊 Latest Financial Highlights FY26 Consolidated PAT: ₹195 crore, up 16% YoY from ₹168 crore. Revenue: ₹2,568 crore, up 6.8% YoY. EBITDA: ₹312 crore, despite margin pressures from start-up costs and geopolitical headwinds. Q1FY27 Revenue: ₹703.6 crore, up 19% YoY, driven by API price hikes and volume growth. Q1FY27 EBITDA: ₹96.9 crore, margins expanded to 13.8%. 🏢 Corporate & Management Updates Leadership Transition: Shri Prakash M. Patil retired as Chairman, MD & CEO on 30 Sept 2026. Adhish P. Patil promoted from CFO to MD effective 1 Oct 2026. Shri Rashesh C. Gogri appointed as Chairman. Performance Stock Option Plan (PSOP 2026): Approved at AGM with 84.8% shareholder support, though institutional investors voted 99.7% against. Up to 8 lakh performance stock options authorized. 📈 Stock Performance & Technicals Latest Price: Around ₹402.25 (NSE/BSE). Day Range: ₹380.85 – ₹404.80. 52-Week Range: ₹318.95 – ₹534.00. Recent Move: +6.04% on 27 Oct 2026. Technical Outlook: Momentum shifted from sideways to mildly bullish. Daily moving averages turning positive. Weekly MACD mildly bearish, monthly MACD mildly bullish (mixed signals). RSI neutral, suggesting room for directional movement. ⚠️ Risks & Watchpoints Geopolitical Risks: Raw material supply chain pressures, especially ammonia. Institutional Resistance: Strong opposition to PSOP 2026 may signal governance concerns. Market Volatility: Despite PAT growth, margins remain sensitive to raw material inflation.

PLI Schemes Boost ₹50,000+ Crore Pharma & MedTech Investment

India’s Production Linked Incentive (PLI) schemes are significantly expanding domestic manufacturing capabilities across bulk drugs, pharmaceuticals, and medical devices, driving investment and curbing import reliance. The PLI Scheme for Bulk Drugs, launched with a ₹6,940 crore ($948.09 million) outlay, targets 41 critical Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates. As of June 2026, actual investment has reached ₹5,210.74 crore ($548.68 million)—surpassing committed targets—with 39 commissioned projects producing 28 critical inputs, including fermentation-based compounds like Penicillin-G, Clavulanic Acid, and Rifampicin. This framework has generated cumulative sales of ₹3,792.49 crore ($399.33 million), including ₹560.16 crore ($58.98 million) in exports, while supporting over 5,100 domestic jobs. Concurrently, the ₹15,000 crore ($2.02 billion) PLI Scheme for Pharmaceuticals has mobilized massive capital toward biopharmaceuticals, complex generics, orphan drugs, and high-value formulations. Encompassing 55 selected applicants—including 20 MSMEs—the scheme attracted ₹46,744 crore ($4.92 billion) in actual investment against a ₹17,275 crore target, yielding ₹4.03 lakh crore ($42.42 billion) in cumulative sales, ₹2.57 lakh crore ($27.10 billion) in exports, and over 1.21 lakh jobs. Complementing these efforts, the ₹3,420 crore ($467.21 million) PLI Scheme for Medical Devices has operationalized domestic production for 57 advanced devices, such as MRI machines, CT scanners, Cath Labs, and linear accelerators, reinforcing India's industrial resilience across the healthcare supply chain. AARTIDRUGS

Aarti Drugs: Moving up the pharma value chain

AARTIDRUGS # Aarti Drugs: Moving up the pharma value chain Aarti Drugs Limited is moving beyond its traditional API business through backward integration, formulations and CDMO opportunities. The company plans ₹150–200 crore of annual capex for the next two years. The key focus is metformin. Aarti Drugs has already increased capacity to around 1,450–1,500 tonnes per month and plans to take this to 1,800–1,900 tonnes. It is also pursuing US FDA approval and plans to forward-integrate into metformin formulations. The company is also exploring CDMO opportunities in chlorosulfonation chemistry, where it already has manufacturing expertise, while expanding cardiovascular and antifungal products. This matters because APIs are more exposed to pricing cycles. Moving further downstream into regulated formulations and specialised manufacturing can potentially improve realisations and margins. Aarti Drugs has already completed around ₹600 crore of capex across Sayakha and Tarapur, while management estimates more than ₹1,200 crore of revenue potential from completed projects. **My view:** The interesting part of Aarti Drugs is the transition from an API-led business toward a more integrated pharma platform. The key test is whether the new capacity gets utilised fast enough to generate attractive returns on the capital invested. **What I'm watching:** Sayakha utilisation, metformin forward integration, regulated-market approvals, CDMO wins and return on capital. **Stance:** Capacity creation is only the first step. Execution and utilisation will determine whether the investment cycle translates into sustainable earnings growth. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

Aarti Drugs Ltd latest updates centre on its FY26

AARTIDRUGS latest updates centre on its FY26 full-year results, a management transition, and corporate actions ahead of its 41st AGM. For the year ended 31 March 2026, the company reported consolidated revenue of ₹2,568 crore, up 6.8% year on year, and consolidated PAT of ₹195 crore, up 16%, driven by new facility commercialisation and a higher share of regulated-market sales, even as raw-material cost volatility remained a concern. In Q1 FY27 (June 2026), consolidated revenue grew 19% to ₹703.6 crore and EBITDA rose 30% to ₹96.9 crore with margin expanding to 13.8%, while net profit dipped 7.1% to ₹50.1 crore due to a prior-year tax-refund base effect. The company has announced a leadership change effective October 2026, with Rashesh C. Gogri taking over as Chairman and Adhish P. Patil as Managing Director, as part of succession planning. The board also approved a Performance Stock Option Plan 2026 for up to 8 lakh options, subject to shareholder approval. Aarti Drugs will hold its 41st AGM on 26 September 2026 via video conference, with the record date for voting eligibility on 19 September and remote e-voting from 23–25 September.